

Remarks

The above Amendments and these Remarks are in reply to the Office action mailed December 18, 2001. Applicant will address the Examiner's Remarks in the order presented in the Office action.

Specification

The Examiner has noted that the sequence on page 9, line 27 does not have a Seq. ID number. Applicant has amended the specification to add a Seq ID number, and has enclosed a CRF and paper copy of the Sequence Listing, including SEQUENCE ID NO.

3. These documents were forwarded previously to the Examiner.

Applicants confirm that both the CRF and paper copy of the Sequence Listing are identical, and no new matter has been added.

Claim Rejections 35 U.S.C. §112, Second Paragraph

Claims 8-12 stand rejected under §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which Applicant regards as the invention. The Examiner has stated that claims 8-11 are indefinite as they are directed to a protein of a specified sequence, but refer to the "protein" as "protein(s)." Specifically, the Examiner has rejected claims 8-11 because the Examiner believes that it is unclear if the protein(s) are a group of different proteins, of which one has the specified sequence. Additionally, the Examiner has requested that if "protein(s)" is referring to a protein, which comprises the specified sequence, "protein(s)" should be replaced with "protein." Applicant has obviated the rejection by amending claims 8-11 to delete "protein(s)," and in its place have substituted "protein."

The Examiner has rejected claim 8 as being indefinite as the claim is drawn to a protein "encoding an amino acid sequence comprising SEQ ID NO: 2 or SEQ ID NO: 1."

SEQ ID NO: 1 refers to a polynucleotide sequence. Thus, the Examiner will note that claim 8 has been further amended to delete reference to "SEQ ID NO: 1," as well as the phrase "encoding an amino acid sequence." Finally, "binds" has been deleted and "bind" substituted in its place.

The Examiner has rejected claim 9 as being indefinite as the protein of claim 8 does not further comprise a bromodomain since the bromodomain is already present in SEQ ID NO: 2. Claim 9 has been amended as suggested by the Examiner to delete "which further comprises a bromodomain comprising" and substituted in its place "wherein a bromodomain comprises."

The Examiner has rejected claim 10 as being indefinite as it refers to the amino acid sequence "shown in SEQ ID NO: 2" and the cDNA "shown in SEQ ID NO: 1." Applicant has amended claim 10 to delete "shown in," and substituted in its place "as set forth."

The Examiner has rejected claim 12 as being indefinite because it depends upon an indefinite base claim and fails to correct the problem. Applicant has amended claim 12 indirectly by way of amendment to claim 11, wherein "proteins" has been deleted and substituted with "protein."

35 U.S.C. § 112 Claim Rejections, First Paragraph

The Examiner has stated that claims 8 and 9 stand rejected under 35 U.S.C. § 112, first paragraph, because the specification while being enabled for an isolated phosphatidylinositol-3' kinase associated protein comprising the amino acid sequence of SEQ ID NO: 2 or encoded by SEQ ID NO: 1, does not reasonably provide enablement for any phosphatidylinositol-3' kinase associated protein that binds to the intermediate SH2 domain on the regulatory subunit of phosphatidylinositol-3' kinase. Applicant

believes that this rejection is obviated by amending the claims to delete "proteins" and substituting therefore "protein."

The Examiner will note that the Applicant has added a new claim, claim 23.


In view of the above Amendments and Remarks, reconsideration of the pending claims is requested.

Applicants attach Exhibit A, Pending Claims After Instant Amendment, pursuant to 37 C.F.R. §1.121.

The Commissioner is authorized to charge any fees associated with this communication to Deposit Account No. 15-0615 for any matter in connection with this response, including any fee for extension of time which may be required. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

Date: April 3, 2003

By: 
Gregory Giotta, Ph.D.
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 262-8710
Facsimile (510) 222-9758

EXHIBIT A

Pending Claims after Instant Amendment

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Canceled)
7. (Canceled)
8. (Twice Amended) An isolated phosphatidylinositol-3' kinase associated protein [protein(s) encoding an amino acid sequence] comprising SEQ ID No. 2 [r SEQ ID No. 1,] and that binds [bind] to the intermediate SH2 domain on the regulatory subunit of phosphatidylinositol-3' kinase by the associated protein(s) C-terminal amino acids.
9. (Twice Amended) An isolated phosphatidylinositol-3' kinase associated [protein(s)] protein of claim 8 wherein [which further comprises] a bromodomain comprises [comprising] amino acids 151-313 of SEQ ID No. 2.
10. (Twice Amended) An isolated phosphatidylinositol-3' kinase associated protein [protein(s)] of claim 9 comprising the amino acid sequence [shown] as set forth in SEQ ID No. 2, or the amino acid sequence encoded by the cDNA [shown] as set forth in SEQ ID No. 1
11. (Once Amended) A chimeric protein comprising said phosphatidylinositol-3' kinase associated protein(s) of claim 10 fused to a heterologous polypeptide.

12. (Previously Amended): The chimeric protein of Claim 11 in which the heterologous polypeptide is an epitope tag
13. (Canceled)
14. (Canceled)
15. (Canceled)
16. (Canceled)
17. (Canceled)
18. (Canceled)
19. (Canceled)
20. (Canceled)
21. (Canceled)
22. (Canceled)
23. (New) An isolated phosphatidylinositol-3' kinase associated protein comprising an amino acid sequence which is encoded by a nucleotide sequence which hybridizes under stringent conditions to the nucleotide sequence set forth in SEQ ID No. 1.